2.42
Neuraxis Inc stock is traded at $2.42, with a volume of 30,126.
It is down -2.42% in the last 24 hours and down -11.36% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.48
Open:
$2.48
24h Volume:
30,126
Relative Volume:
0.02
Market Cap:
$23.72M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.0002
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+2.11%
1M Performance:
-11.36%
6M Performance:
+2.98%
1Y Performance:
-12.95%
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NRXS
Neuraxis Inc
|
2.42 | 23.72M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Stock (NRXS) Latest News
Neuraxis announces new medical policy with two health insurers - TipRanks
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives - GlobeNewswire
NeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal Pain - Nasdaq
NeurAxis (NASDAQ:NRXS) Now Covered by Analysts at Craig Hallum - Defense World
Neuraxis (NRXS) Initiated with Buy Rating by Craig-Hallum | NRXS Stock News - GuruFocus
Craig-Hallum initiates NeurAxis stock with buy rating on pediatric device - Investing.com India
Craig-Hallum bullish on Neuraxis, initiates with a Buy - TipRanks
Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain in Ibs - MarketScreener
NeurAxis (NRXS) Gains Momentum with Key Guideline Inclusion | NR - GuruFocus
Neuraxis secures key academic society guidelines recommendation for FAP - TipRanks
NeurAxis Achieves Critical Milestone; Secures Key Academic - GlobeNewswire
Major Medical Guidelines Back NeurAxis $3B IBS Treatment for Children, Only FDA-Cleared Option - Stock Titan
47,094 Shares in NeurAxis, Inc. (NASDAQ:NRXS) Bought by Citadel Advisors LLC - Defense World
NeurAxis, Inc. Approves Key Proposals at Annual Meeting - TipRanks
NeurAxis, Inc. Releases Investor Presentation - TipRanks
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times
Biotech Alert: Searches spiking for these stocks today - TipRanks
NeurAxis Closes $5 Million Direct Offering - marketscreener.com
NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire
NeurAxis announces USD 5M registered direct offering - Medical Buyer
NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks
Form 424B5 Neuraxis, INC - StreetInsider
SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow
Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa
NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks
Neuraxis settles lawsuit with $750,000 agreement - Investing.com
NeurAxis slides 21%, raises $5M via stock - MSN
Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize
NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq
NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus
NeurAxis Launches $5 Million Direct Offering - marketscreener.com
NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus
Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks
NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times
NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire
NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com
NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com
NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph
Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent
Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga
NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com
NeurAxis, Inc. Receives First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia and Associated Nausea Symptoms - marketscreener.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Cap:
|
Volume (24h):